Yousif Capital Management LLC Has $19.07 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Yousif Capital Management LLC decreased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 39,316 shares of the medical research company’s stock after selling 1,584 shares during the quarter. Yousif Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $19,069,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Trust Co. of Vermont grew its holdings in shares of Thermo Fisher Scientific by 3.0% during the 3rd quarter. Trust Co. of Vermont now owns 47,994 shares of the medical research company’s stock worth $23,278,000 after purchasing an additional 1,378 shares in the last quarter. Farther Finance Advisors LLC grew its stake in Thermo Fisher Scientific by 17.5% during the third quarter. Farther Finance Advisors LLC now owns 7,688 shares of the medical research company’s stock worth $3,729,000 after buying an additional 1,144 shares in the last quarter. Parcion Private Wealth LLC raised its position in shares of Thermo Fisher Scientific by 21.1% in the 3rd quarter. Parcion Private Wealth LLC now owns 890 shares of the medical research company’s stock valued at $432,000 after buying an additional 155 shares in the last quarter. Roffman Miller Associates Inc. PA boosted its position in shares of Thermo Fisher Scientific by 2.6% during the 3rd quarter. Roffman Miller Associates Inc. PA now owns 39,977 shares of the medical research company’s stock worth $19,389,000 after acquiring an additional 1,024 shares in the last quarter. Finally, Elevation Wealth Partners LLC increased its stake in Thermo Fisher Scientific by 35.1% in the third quarter. Elevation Wealth Partners LLC now owns 77 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 20 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have weighed in on TMO shares. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday, October 23rd. JPMorgan Chase & Co. raised their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research note on Thursday, October 9th. Morgan Stanley boosted their target price on Thermo Fisher Scientific from $656.00 to $670.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 2nd. Barclays raised their price target on shares of Thermo Fisher Scientific from $585.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. Finally, Hsbc Global Res upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Monday, December 1st. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $616.60.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $575.85 on Tuesday. The stock has a market cap of $216.35 billion, a price-to-earnings ratio of 33.27, a P/E/G ratio of 4.21 and a beta of 0.90. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97. The company’s fifty day moving average is $570.03 and its 200 day moving average is $499.31. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.50 by $0.29. The business had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.Thermo Fisher Scientific’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period last year, the company earned $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is currently 9.94%.

Thermo Fisher Scientific announced that its board has approved a stock repurchase program on Thursday, November 6th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.

Insider Activity

In other news, CEO Marc N. Casper sold 17,104 shares of the business’s stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $573.54, for a total value of $9,809,828.16. Following the transaction, the chief executive officer owned 113,762 shares in the company, valued at approximately $65,247,057.48. The trade was a 13.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Michel Lagarde sold 32,000 shares of the stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $583.39, for a total transaction of $18,668,480.00. Following the sale, the chief operating officer owned 65,480 shares of the company’s stock, valued at approximately $38,200,377.20. This trade represents a 32.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 149,271 shares of company stock worth $86,507,282. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.